Navigation Links
MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Date:5/5/2009

Results Showing Burden of RSV Disease Presented at Pediatric Academic Societies' Annual Meeting

BALTIMORE, May 5 /PRNewswire/ -- MedImmune today announced results from a recent study it sponsored, performed by the Kaiser Permanente Division of Research in Oakland, CA, assessing risk factors for respiratory syncytial virus (RSV) infection requiring medical treatment in infants born at 33 weeks gestational age [GA] or later. The analysis suggested that even mild prematurity (e.g., babies born 33-36 weeks GA) is associated with increased risk of medically attended RSV infection, and that this risk is higher among infants exposed to supplemental oxygen or assisted ventilation during the neonatal period. These findings were presented at the 2009 Pediatric Academic Societies (PAS) Annual Meeting in Baltimore, Maryland by Dr. Gabriel J. Escobar.

RSV is a leading cause of viral respiratory infection among preterm infants. Although prematurity is a known risk factor for severe RSV infection, there is little information available on risk factors among moderately (rather than extremely) premature babies.

"The health risks associated with late-preterm birth may be overlooked or misunderstood because these babies often appear as healthy as full-term infants. This study contributes to the growing evidence that, late-preterm infants face greater morbidity and healthcare costs up to at least one year after birth," noted Parthiv Mahadevia, M.D., senior director, health outcomes and pharmacoeconomics, MedImmune. "In particular, babies born between 33 and 36 weeks GA have under-developed respiratory and immune systems, putting them at heightened risk for severe RSV disease. Doctors, parents, and the health care system should be aware of these babies' specialized health needs.

This study sought to quantify the relationships between neonatal characteristics and the occurrence of RSV infection requiring medica
'/>"/>

SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
2. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
3. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
4. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
5. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
7. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
8. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
9. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
10. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Reportlinker.com announces that ... its catalogue: Antibody Drug Conjugates Market ... http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html INTRODUCTION Antibody ... therapeutic agents, gaining increasing attention from both large ... marriage of an antibody with a toxic drug ...
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- SAM ... (Axilla) Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that ... recall to address a potential issue with a ... for the Axilla application of the SAM Junctional ...
Breaking Medicine Technology:Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
... , TUCSON, Ariz. , Feb. 4 ... care. Arizona Oncology physicians will now treat patients at Marana Healthcare Clinic ... medical oncologists, are now actively caring for patients at MHC. , "We ... "By providing cancer care services in Marana we are able ...
... , SUNNYVALE, Calif. , Feb. 4 ... of radiosurgery, announced today financial results for the second quarter of fiscal ... second quarter of fiscal 2010, Accuray reported total revenue of $57.3 ... of $57.6 million . , Accuray reported a net loss ...
Cached Medicine Technology:Cancer Patients in Marana Now Have Local Access to Advanced Cancer Care 2Cancer Patients in Marana Now Have Local Access to Advanced Cancer Care 3Cancer Patients in Marana Now Have Local Access to Advanced Cancer Care 4Accuray Announces Results for Second Quarter Fiscal 2010 2Accuray Announces Results for Second Quarter Fiscal 2010 3Accuray Announces Results for Second Quarter Fiscal 2010 4Accuray Announces Results for Second Quarter Fiscal 2010 5Accuray Announces Results for Second Quarter Fiscal 2010 6Accuray Announces Results for Second Quarter Fiscal 2010 7Accuray Announces Results for Second Quarter Fiscal 2010 8Accuray Announces Results for Second Quarter Fiscal 2010 9Accuray Announces Results for Second Quarter Fiscal 2010 10Accuray Announces Results for Second Quarter Fiscal 2010 11Accuray Announces Results for Second Quarter Fiscal 2010 12
(Date:9/1/2014)... Wellesley, Mass., (PRWEB) September 01, 2014 ... report, BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS ... reached $21.8 million in 2013 and is expected to ... further grow to $471.5 million by 2019, which is ... 2014 through 2019. The receptor-mediated transport (RMT) segment is ...
(Date:9/1/2014)... 2014 Parties involved in federally-filed Tylenol ... litigation’s status conference in September, where issues related to ... the Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. ... posted on the Court’s website, the meeting is scheduled ... a.m. This is the latest of several Tylenol conferences ...
(Date:9/1/2014)... Ontraport , one of the latest ... to automate the small intricacies of managing an online ... prompting an investigative review. , “As a new ... all of the small details involved with running a ... “That’s why Ontraport has become so popular in this ...
(Date:9/1/2014)... AttorneyOne.com, a recognized authority on law, update ... the FDA on DePuy Synthes Craniomaxillofacial Distraction System ... 28, that specific lots of DePuy Synthes Craniomaxillofacial Distraction ... device may reverse directions after surgery. According to ... is an implant used to lengthen and/or stabilize the ...
(Date:9/1/2014)... 01, 2014 Beginning Tuesday, September 2nd, ... medical professionals and 10,000 consumers for the annual gathering ... gathering of the nation’s top medical professionals who specializes ... conditions. The week-long event contains more than 120 hours ... available in the pain management field. , MarijuanaDoctors.com is ...
Breaking Medicine News(10 mins):Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2
... the largest study of its kind for the genetic roots ... Disease as well as further evidence that some people of ... study examined changes in DNA associated with the two most ... which is most frequently marked by inflammation of the final ...
... Assessment Tools To ... Healthier Lifestyles, NEW YORK, March 26 EnergyNow!, ... and fitness,technology fields, today announced the availability of a ... Delaware, Maryland,Pennsylvania, Virginia, West Virginia and Washington D.C. combat ...
... Governor Edward G.,Rendell today announced the state,s new ... ahead to better meet their future,long-term care needs., ... be put off. If,people do fail to prepare, it ... "The ,Own Your Future, campaign,empowers consumers to take steps ...
... Award-Winning Mind Fitness Company, WASHINGTON, March 26 ... Ltd., the company that uses the latest scientific,research ... cognitive,performance and health, today announced that it will ... the American Society on Aging,(ASA), as a consultant., ...
... Technologies(R),Inc. ("Global Med" or the "Company") (OTC Bulletin ... announced,the sale yesterday, March 25, 2008, of approximately ... was held by SingXpress Ltd., an Asian company,(previously ... were sold,to five American institutions and the transaction ...
... lower health-related quality of life for their children ... from the parents of healthy children. However, reports ... These findings are published in the April issue ... online at Wiley Interscience (www.interscience.wiley.com ). , Children ...
Cached Medicine News:Health News:Large multicenter study suggests new genetic markers for Crohn's disease 2Health News:EnergyNow! Announces New Grant Funding to Combat Childhood Obesity 2Health News:EnergyNow! Announces New Grant Funding to Combat Childhood Obesity 3Health News:Governor Rendell Announces 'Own Your Future' Campaign; Urges Consumers to Better Plan Their Long-Term Care Needs 2Health News:CogniFit to Work With Gloria Cavanaugh, Former ASA President 2Health News:Global Med Technologies(R), Inc. Announces the Sale of Approximately 3.3 Million Shares of Global Med Common Stock Held by SingXpress Ltd., an Asian Company, to Five American Institutions 2Health News:Study shows lifetime effects of pediatric liver transplants 2
... Lyphochek Immunoassay Plus Control provides ... comprehensive control in the world for ... procedures, eliminating the need for separate ... no added preservatives, it is suitable ...
... Plus Control is a liquid ... today's busy immunoassay laboratory. With ... human serum based control can ... control products for immunoassay and ...
Liquichek Immunology Control is a trilevel, liquid, comprehensive serum protein control with assayed values for a wide number of methods....
... Detection Platform provides fully automated detection of ... platform for molecular pathology labs separates DNA ... features that deliver a high degree of ... the capacity to run two 96-well plates, ...
Medicine Products: